206 related articles for article (PubMed ID: 21860550)
1. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.
Park HS; Choi JY; Lee MJ; Park S; Yeo CW; Lee SS; Shin JG; Park BW
J Korean Med Sci; 2011 Aug; 26(8):1007-13. PubMed ID: 21860550
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Brooks JD; Comen EA; Reiner AS; Orlow I; Leong SF; Liang X; Mellemkjær L; Knight JA; Lynch CF; John EM; Bernstein L; Woods M; Doody DR; ; Malone KE; Bernstein JL
Breast Cancer Res; 2018 Dec; 20(1):149. PubMed ID: 30526633
[TBL] [Abstract][Full Text] [Related]
6. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
[TBL] [Abstract][Full Text] [Related]
9. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
[TBL] [Abstract][Full Text] [Related]
13. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
Teh LK; Mohamed NI; Salleh MZ; Rohaizak M; Shahrun NS; Saladina JJ; Shia JK; Roslan H; Sood S; Rajoo TS; Muniandy SP; Henry G; Ngow HA; Hla U KT; Din J
AAPS J; 2012 Mar; 14(1):52-9. PubMed ID: 22183189
[TBL] [Abstract][Full Text] [Related]
14. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
15. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.
Li J; Czene K; Brauch H; Schroth W; Saladores P; Li Y; Humphreys K; Hall P
Breast Cancer Res; 2013; 15(5):R93. PubMed ID: 24088226
[TBL] [Abstract][Full Text] [Related]
18. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
Lee CI; Low SK; Maldonado R; Fox P; Balakrishnar B; Coulter S; de Bruijn P; Koolen SLW; Gao B; Lynch J; Zdenkowski N; Hui R; Liddle C; Mathijssen RHJ; Wilcken N; Wong M; Gurney H
Breast; 2020 Dec; 54():229-234. PubMed ID: 33161337
[TBL] [Abstract][Full Text] [Related]
19. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
He W; Grassmann F; Eriksson M; Eliasson E; Margolin S; Thorén L; Hall P; Czene K
J Clin Oncol; 2020 Feb; 38(6):548-557. PubMed ID: 31800347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
